Joel Greenblatt's BCRX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 216,946 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $1.69 M, representing 0.01% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in BCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 157,749 shares. Largest reduction occurred in Q4 2025, reducing 126,825 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -126,825 | Reduce 36.89% | 216,946 | $7.80 |
| Q3 2025 | +141,958 | Add 70.34% | 343,771 | $7.59 |
| Q2 2025 | +157,749 | Add 358.00% | 201,813 | $8.96 |
| Q1 2025 | +44,064 | New Buy | 44,064 | $7.50 |
| Q4 2024 | -38,893 | Sold Out | 0 | $0.00 |
| Q3 2024 | +38,893 | New Buy | 38,893 | $7.60 |
| Q4 2023 | -69,033 | Sold Out | 0 | $0.00 |
| Q3 2023 | +69,033 | New Buy | 69,033 | $7.08 |
| Q4 2022 | -24,034 | Sold Out | 0 | $0.00 |
| Q3 2022 | +24,034 | New Buy | 24,034 | $12.61 |
| Q2 2022 | -14,548 | Sold Out | 0 | $0.00 |
| Q1 2022 | +3,240 | Add 28.65% | 14,548 | $16.29 |
| Q4 2021 | +11,308 | New Buy | 11,308 | $13.88 |
| Q3 2021 | -48,641 | Sold Out | 0 | $0.00 |
| Q2 2021 | +48,641 | New Buy | 48,641 | $15.81 |
| Q1 2021 | -14,658 | Sold Out | 0 | $0.00 |
| Q4 2020 | +694 | Add 4.97% | 14,658 | $7.44 |
| Q3 2020 | -1,176 | Reduce 7.77% | 13,964 | $3.44 |
| Q2 2020 | -13,228 | Reduce 46.63% | 15,140 | $4.76 |
| Q1 2020 | +28,368 | New Buy | 28,368 | $2.01 |
| Q2 2017 | -126,553 | Sold Out | 0 | $0.00 |
| Q1 2017 | +126,553 | New Buy | 126,553 | $8.40 |
| Q1 2016 | -19,424 | Sold Out | 0 | $0.00 |
| Q4 2015 | +19,424 | New Buy | 19,424 | $10.30 |
Joel Greenblatt's BioCryst Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q4 2015, acquiring 19,424 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held BioCryst Pharmaceuticals, Inc. (BCRX) for 24 quarters since Q4 2015.
Joel Greenblatt's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q2 2025, adding 201,813 shares worth $1.81 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 216,946 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $1.69 M.
As of the Q4 2025 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 343,771 shares, as reported at the end of Q3 2025.